Endocyte Stockholders Approve Merger Agreement with Novartis AG
20 déc. 2018 09h25 HE
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced...
Endocyte Provides Third Quarter 2018 Financial Results and Operational Update
07 nov. 2018 16h01 HE
|
Endocyte, Inc.
Entered into agreement and plan of merger with Novartis AG for $2.1Billion WEST LAFAYETTE, Ind., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical...
Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion
18 oct. 2018 01h10 HE
|
Endocyte, Inc.
Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE...
Endocyte to Present at Two Investor Conferences on October 2nd
27 sept. 2018 08h01 HE
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
Endocyte Announces Closing of Public Offering of Common Stock
14 sept. 2018 16h01 HE
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
Endocyte Announces Pricing of Public Offering of Common Stock
11 sept. 2018 19h53 HE
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock
10 sept. 2018 16h15 HE
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)
10 sept. 2018 08h00 HE
|
Endocyte, Inc.
Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval A positive assessment on either rPFS or OS is sufficient for full approval rPFS analysis...
Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference
29 août 2018 08h01 HE
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018
28 août 2018 17h04 HE
|
Endocyte, Inc.
WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...